IL152360A0 - Sustained release formulations - Google Patents
Sustained release formulationsInfo
- Publication number
- IL152360A0 IL152360A0 IL15236001A IL15236001A IL152360A0 IL 152360 A0 IL152360 A0 IL 152360A0 IL 15236001 A IL15236001 A IL 15236001A IL 15236001 A IL15236001 A IL 15236001A IL 152360 A0 IL152360 A0 IL 152360A0
- Authority
- IL
- Israel
- Prior art keywords
- sustained release
- release formulations
- crytallize
- polymeric
- viscosity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 239000011344 liquid material Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19820900P | 2000-04-19 | 2000-04-19 | |
PCT/US2001/012909 WO2001078683A2 (fr) | 2000-04-19 | 2001-04-19 | Formulations a liberation lente |
Publications (1)
Publication Number | Publication Date |
---|---|
IL152360A0 true IL152360A0 (en) | 2003-05-29 |
Family
ID=22732439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15236001A IL152360A0 (en) | 2000-04-19 | 2001-04-19 | Sustained release formulations |
Country Status (11)
Country | Link |
---|---|
US (1) | US6992065B2 (fr) |
EP (1) | EP1274459B1 (fr) |
JP (1) | JP4361710B2 (fr) |
AT (1) | ATE309822T1 (fr) |
AU (2) | AU5911101A (fr) |
CA (1) | CA2406790C (fr) |
DE (1) | DE60115005T2 (fr) |
DK (1) | DK1274459T3 (fr) |
ES (1) | ES2253375T3 (fr) |
IL (1) | IL152360A0 (fr) |
WO (1) | WO2001078683A2 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1397155B1 (fr) * | 2001-06-21 | 2015-09-30 | Genentech, Inc. | Formulation a liberation lente |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
DE10242088A1 (de) * | 2002-09-11 | 2004-03-25 | Bayer Ag | Kontrolliertes Freisetzungssystem, welches Saccharoseacetatisobutyrat enthält |
EP1575569B1 (fr) | 2002-12-13 | 2010-09-29 | Durect Corporation | Forme d'administration orale de medicaments comprenant un vehicule liquide de haute viscosite |
BR0317421A (pt) * | 2002-12-19 | 2005-11-08 | Alza Corp | Géis de fase única não-aquosa estável e formulações destes para liberação a partir de um dispositivo implantável |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
DE10312346A1 (de) * | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Kontrolliertes Freisetzungssystem |
BRPI0418304A (pt) * | 2004-01-07 | 2007-05-02 | Trimeris Inc | peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv |
LT2767292T (lt) | 2004-09-17 | 2016-12-12 | Durect Corporation | Palaikomosios vietinės anestezijos mišinys su saib |
CA2593112A1 (fr) * | 2005-01-21 | 2006-07-27 | Alza Corporation | Preparations peptidiques therapeutiques a stabilite accrue |
WO2006083761A2 (fr) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solutions de solvant/polymere utilisees comme vehicules de suspension |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US7655254B2 (en) * | 2005-02-03 | 2010-02-02 | Intarcia Therapeutics, Inc. | Implantable device for continuous delivery of interferon |
US8329207B2 (en) | 2005-05-23 | 2012-12-11 | Natural Alternatives International, Inc. | Compositions and methods for the sustained release of beta-alanine |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
US7456251B2 (en) * | 2006-02-02 | 2008-11-25 | Trimeris, Inc. | HIV fusion inhibitor peptides with improved biological properties |
DE602007009377D1 (de) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem |
KR101200728B1 (ko) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 삼투성 전달 시스템 및 피스톤 조립체 |
AU2007325918B2 (en) | 2006-11-03 | 2013-10-17 | Durect Corporation | Transdermal delivery systems comprising bupivacaine |
US20080140106A1 (en) * | 2006-12-12 | 2008-06-12 | Kimberly-Clark Worldwide, Inc. | Enhanced cuff sealing for endotracheal tubes |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
CN101678125A (zh) * | 2007-04-03 | 2010-03-24 | 特里梅里斯公司 | 用于递送抗病毒肽治疗剂的新制剂 |
WO2008133908A2 (fr) | 2007-04-23 | 2008-11-06 | Intarcia Therapeutics, Inc. | Formulations en suspension de peptides insulinotropes et leurs utilisations |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
JP5323832B2 (ja) | 2007-08-07 | 2013-10-23 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 酸性水溶液中にgdf−5を含むタンパク質製剤 |
BRPI0817697A2 (pt) * | 2007-09-25 | 2015-04-07 | Trimeris Inc | Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo |
US8114883B2 (en) | 2007-12-04 | 2012-02-14 | Landec Corporation | Polymer formulations for delivery of bioactive materials |
EP2067471B1 (fr) * | 2007-12-06 | 2018-02-14 | Durect Corporation | Formes orales de dosage pharmaceutique |
US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
CN102131483A (zh) * | 2008-02-08 | 2011-07-20 | 昌达生物科技公司 | 可控给药非聚合组合物 |
CN102231981A (zh) | 2008-02-08 | 2011-11-02 | 昌达生物科技公司 | 蛋白质或肽的缓释给药组合物 |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
JP5599778B2 (ja) | 2008-04-14 | 2014-10-01 | デピュイ・シンセス・プロダクツ・エルエルシー | 液体緩衝gdf−5製剤 |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
MX352878B (es) | 2009-09-28 | 2017-12-13 | Intarcia Therapeutics Inc | Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco. |
WO2011073234A2 (fr) | 2009-12-15 | 2011-06-23 | Ascendis Pharma As | Composition d'hormone de croissance |
TWI538687B (zh) * | 2010-11-24 | 2016-06-21 | 杜瑞克公司 | 生物可降解之藥物遞送組成物 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
ITMI20110445A1 (it) * | 2011-03-22 | 2012-09-23 | Lo Li Pharma Srl | Formulazione farmaceutica comprendente inositolo. |
CN103127514B (zh) * | 2011-11-22 | 2014-07-02 | 朱成钢 | 一种可体内注射的药物缓释栓剂 |
CN102389571B (zh) * | 2011-11-22 | 2013-04-24 | 朱成钢 | 一种可体内注射的药物缓释栓剂 |
WO2014144975A1 (fr) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions ayant un agent de modification rhéologique pour réduire une variabilité de dissolution |
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP4278996A3 (fr) | 2015-06-03 | 2024-01-24 | i2o Therapeutics, Inc. | Systèmes de mise en place d'implant |
EP3458084B1 (fr) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
MX2019008006A (es) | 2017-01-03 | 2019-08-29 | Intarcia Therapeutics Inc | Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco. |
WO2019060921A1 (fr) | 2017-09-25 | 2019-03-28 | Bolt Threads, Inc. | Procédés de génération de fibres de protéine de soie d'araignée de recombinaison hautement cristallines |
CN112566767A (zh) * | 2018-08-10 | 2021-03-26 | 保尔特纺织品公司 | 用于模制体的组合物 |
CA3167217A1 (fr) | 2020-01-13 | 2021-07-22 | Durect Corporation | Systemes d'administration de medicament a liberation prolongee avec impuretes reduites et procedes associes |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4016273A (en) * | 1975-07-16 | 1977-04-05 | American Cyanamid Company | Sustained release forms of certain oxazepines for parenteral administration |
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
US5411951A (en) * | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
IL79681A (en) | 1985-08-12 | 1991-06-10 | Int Minerals & Chem Corp | Transition metal complexes of growth hormones and their prolonged release compositions |
WO1989003671A1 (fr) | 1987-10-29 | 1989-05-05 | Dainippon Pharmaceutical Co., Ltd. | Preparation a liberation entretenue |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4975271A (en) | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
US5324520A (en) | 1988-12-19 | 1994-06-28 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
US5133981A (en) | 1989-11-17 | 1992-07-28 | Atrix Laboratories, Inc. | Purification of benzophenanthridine alkaloids extracts from alkaloid extracts |
PT99345A (pt) | 1990-10-30 | 1992-09-30 | Alza Corp | Processo para a preparacao de sistemas apropriados para a libertacao de agentes terapeuticos |
US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
AU1757092A (en) * | 1991-03-28 | 1992-11-02 | Genentech Inc. | Stable growth hormone metal ion formulations |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5242910A (en) | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
WO1994012158A1 (fr) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Microspheres contenant une hormone de croissance a liberation regulee |
DE69426292T2 (de) | 1993-02-23 | 2001-05-17 | Genentech Inc | Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6080429A (en) | 1993-10-25 | 2000-06-27 | Genentech, Inc. | Method for drying microspheres |
DE69508985T2 (de) | 1994-02-21 | 1999-08-19 | Takeda Chemical Industries Ltd | Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe |
US5556905A (en) | 1994-03-30 | 1996-09-17 | Reilly Industries, Inc. | Physically-modified degradable thermoplastic compositions |
DE69524398T2 (de) | 1994-04-08 | 2002-07-18 | Atrix Lab Inc | Flüssige mittel zur wirkstoffabgabe |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
CA2192773C (fr) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Obtention d'une preparation a liberation prolongee pour injection |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5981489A (en) | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
US5851229A (en) | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
AU7871298A (en) | 1996-12-20 | 1998-07-17 | Takeda Chemical Industries Ltd. | Method of producing a sustained-release preparation |
CA2275587C (fr) | 1996-12-20 | 2006-10-24 | Alza Corporation | Composition de gel injectable a effet retard et son procede de preparation |
US6051558A (en) | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US6113947A (en) | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
US6039977A (en) | 1997-12-09 | 2000-03-21 | Alza Corporation | Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods |
CA2316539C (fr) * | 1997-12-26 | 2008-11-18 | Yamanouchi Pharmaceutical Co., Ltd. | Composition pharmaceutique a liberation prolongee |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
DK1140018T3 (da) | 1998-12-23 | 2004-02-02 | Amgen Inc | Polyol/olie-suspensioner til vedvarende frigørelse af proteiner |
WO2000078335A1 (fr) * | 1999-06-18 | 2000-12-28 | Southern Biosystems, Inc. | Compositions pour la liberation regulee de l'hormone gnrh et ses analogues |
US6245806B1 (en) | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
AU2001271491A1 (en) * | 2000-06-26 | 2002-01-08 | Monsanto Technology Llc | Non-aqueous surfactant-containing formulations for extended release of somatotropin |
-
2001
- 2001-04-19 JP JP2001575984A patent/JP4361710B2/ja not_active Expired - Fee Related
- 2001-04-19 ES ES01932596T patent/ES2253375T3/es not_active Expired - Lifetime
- 2001-04-19 DE DE60115005T patent/DE60115005T2/de not_active Expired - Lifetime
- 2001-04-19 AT AT01932596T patent/ATE309822T1/de not_active IP Right Cessation
- 2001-04-19 AU AU5911101A patent/AU5911101A/xx active Pending
- 2001-04-19 AU AU2001259111A patent/AU2001259111B2/en not_active Ceased
- 2001-04-19 DK DK01932596T patent/DK1274459T3/da active
- 2001-04-19 IL IL15236001A patent/IL152360A0/xx not_active IP Right Cessation
- 2001-04-19 CA CA002406790A patent/CA2406790C/fr not_active Expired - Fee Related
- 2001-04-19 EP EP01932596A patent/EP1274459B1/fr not_active Expired - Lifetime
- 2001-04-19 WO PCT/US2001/012909 patent/WO2001078683A2/fr active IP Right Grant
- 2001-04-19 US US09/839,684 patent/US6992065B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE309822T1 (de) | 2005-12-15 |
US20020001631A1 (en) | 2002-01-03 |
CA2406790A1 (fr) | 2001-10-25 |
ES2253375T3 (es) | 2006-06-01 |
AU5911101A (en) | 2001-10-30 |
DK1274459T3 (da) | 2006-02-06 |
WO2001078683A2 (fr) | 2001-10-25 |
JP4361710B2 (ja) | 2009-11-11 |
EP1274459B1 (fr) | 2005-11-16 |
CA2406790C (fr) | 2009-07-07 |
US6992065B2 (en) | 2006-01-31 |
JP2004500423A (ja) | 2004-01-08 |
AU2001259111B2 (en) | 2005-12-08 |
DE60115005T2 (de) | 2006-07-27 |
WO2001078683A3 (fr) | 2002-05-30 |
DE60115005D1 (de) | 2005-12-22 |
EP1274459A2 (fr) | 2003-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5911101A (en) | Sustained release formulations | |
EP1017411A4 (fr) | Composition assurant la liberation regulee de l'hormone gnrh et de ses analogues | |
EP1006935A4 (fr) | Systeme d'administration regulee d'un liquide de haute viscosite | |
BG103489A (en) | Ziprasidon preparations | |
CA2338358A1 (fr) | Composes permettant de delivrer des agents actifs et compositions a base de ces composes | |
YU58000A (sh) | Preparati sa neprekidnim oslobađanjem | |
MY122704A (en) | Stable hydrogenated lupulone antibacterial oral compositions | |
MY118835A (en) | Sustained release compositions and the process for their preparation | |
AP1414A (en) | Controlled release galantamine composition. | |
GEP20043203B (en) | EP4 Receptor Selective Agonists in the Treatment of Osteoporosis | |
MY125651A (en) | Eplerenone compositions | |
GEP20022709B (en) | Pharmaceutical Compositions Having Appetite Suppressant Activity | |
MY129356A (en) | Electrospun pharmaceutical compositions | |
HK1002017A1 (en) | Lyospheres comprising gonadotropin | |
GB2354545A (en) | Encapsulated breaker slurry compositions and methods of use | |
HUT67426A (en) | Pharmaceutical compositions containing nifedipine and process for the preparation thereof | |
WO1998029085A3 (fr) | Produit cutane dote de proprietes antimicrobiennes, antivirales, antiseptiques et de cicatrisation continues | |
NZ511085A (en) | Oral pharmaceutical compositions containing buprenorphin | |
HUP0203844A3 (en) | Compound with growth hormone releasing properties, pharmaceutical composition containing it and its use | |
BG105570A (en) | Pharmaceutical compositions for modified release insulin sensitiser | |
EP0905143A3 (fr) | Complexe d'hormone de croissance humaine et de zinc et utilisation | |
HK1036221A1 (en) | Topical composition containing human epidermal growth factor. | |
RO117500B1 (ro) | Compoziţie cosmetică | |
MXPA05013250A (es) | Composicion dental de dulce en contra de la placa. | |
IL140044A0 (en) | Compounds with growth hormone releasing properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |